This remote rigorous three-day program is ideal for basic research and translational biology scientists who are looking for a balanced theoretical vs. laboratory introduction to CRISPR toolkit. Taught by active [….]
‘R’ is a popular statistics software program used widely in various research fields. This live remote two day lecture and hands-on computer based laboratory workshop is designed to introduce bench [….]
This two day live remote program is ideal for basic research and translational biology scientists who work with antibodies on a regular basis. This program which focuses on the types [….]
This four day live remote program is ideal for research and translational biology scientists who are looking for a balanced theoretical and introduction to isolation, quantitation, analysis and engineering of [….]
Arcellx Closes $115 Million Series C Financing to Advance its Pipeline of Adaptive and Controllable Cell Therapies
Arcellx, a privately held clinical- stage biopharmaceutical company, today announced that it raised $115 million in a Series C financing to advance its pipeline of adaptive and controllable cell therapies. The proceeds will support the company’s development of CART-ddBCMA, a BCMA-specific CAR-modified T-cell therapy currently in Phase 1 and anticipated to begin a pivotal trial in 2022. In addition, the funding will support initiation of clinical trials evaluating ACLX-001 and ACLX-002, cell therapies derived from Arcellx’s uniquely controllable ARC-SparX platform, in multiple myeloma (MM) and acute myelogenous leukemia (AML), respectively.
Montgomery College Biotech Training Helps Laid-Off Workers Fill Needed Roles WASHINGTON (7News) — A local college is stepping up to fill two needs: To help some of the many workers who [….]
Novavax Plan Outlines Expansion of Gaithersburg Corporate Campus Company says it could add 400 jobs within four years The biotechnology company Novavax, which is at the forefront of the COVID-19 [….]
Raj Vora is a Life Sciences Core Market Leader, Responsible for business growth, technical expertise, and account management of the DPR Construction’s life sciences portfolio in the region through project and customer development or project-specific roles. Focused on cGMP manufacturing facilities primarily in the cell and gene therapy market and involved in lab, containment, and other research projects.
CARB-X is Funding Baltimore’s Novel Microdevices to Develop a Rapid and Portable Diagnostic for STDs Including Antibiotic-Resistant Infections
CARB-X is funding Novel Microdevices to develop a rapid and portable diagnostic for sexually transmitted diseases including antibiotic-resistant infections New portable battery-powered diagnostic is designed to be easy-to-use in any setting around [….]
Arcellx Announces FDA Clearance of IND Application for ACLX-001, a Controllable Cell Therapy Utilizing the Company’s ARC-SparX Platform, for the Treatment of Multiple Myeloma
Arcellx, a privately held clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for ACLX-001, an engineered cell therapy for the treatment of multiple myeloma.